Featured research and insights
PosterSeptember 18, 2023An analysis of adherence to biologic therapies in patients with Ulcerative Colitis and Crohn’s disease in a large pharmacy chain compared to to a national benchmark
PosterSeptember 18, 2023
Rhuematoid Arthritis (RA) and non-infused biologics: adherence, healthcare cost and utilizationThis is a retrospective cohort study using MarketScan Commercial and Medicare Advantage files to examine medication adherence to RA non-infused biologics and the effect upon outcomes of healthcare costs, hospitalizations, and length of stay.
ArticleAugust 01, 2023
GLP-1 agonists disrupting diabetes adherence quality measuresThis analysis estimated disruptions to quality measures for diabetes adherence for Medicare Part-D payers by GLP-1 in 2022 related to GLP-1 receptor agonists
PublicationJune 29, 2023
Factors Associated with Receipt of mRNA-1273 Vaccine at a United States National Retail Pharmacy During the COVID-19 PandemicOver 80% of patients received their on-time second dose of mRNA-1273 vaccine per CDC recommendations. Patient demographics and community characteristics were associated with vaccine receipt and series completion.
PosterMay 10, 2023
Oral Oncology Proportion of Days Covered (PDC) Associations on Medical Costs and Hospitalization in Medicare MarketScan DataPresents results from a study validating use of an adherence metric for oral antineoplastic medications utilized by cancer patients and outcomes of total medical costs, hospitalizations and length of stay.
PosterMay 07, 2023
Medical costs, hospitalizations, and length of stay associated with discontinuations in cycled oral antineoplastics among Medicare-eligible oncology patientsMarketScan Medicare study sample demonstrated that medication adherence (fewer gaps in medicaton coverage) among patients on cycled oral antineoplastics can lead to lower medical costs, fewer hospitlization events and shorter lenght of stay as compared to lower adherence levels.